Prasugrel gains NICE approval

The UK's drug guidance body has endorsed the use of prasugrel (Efient) in patients with acute coronary syndromes who are undergoing percutaneous coronary intervention.

Prasugrel (Efient) prevents clot formation by binding to the P2Y12 ADP receptor on the surface of platelets, thereby inhibiting platelet activation and aggregation.
Prasugrel (Efient) prevents clot formation by binding to the P2Y12 ADP receptor on the surface of platelets, thereby inhibiting platelet activation and aggregation.

NICE guidance states that prasugrel can be used, in conjunction with aspirin, for the prevention of atherothrombotic events in individuals who:

  • need immediate primary percutaneous coronary intervention for ST-segment-elevation MI, or
  • developed stent thrombosis during clopidogrel treatment, or
  • have diabetes mellitus.

People already receiving prasugrel for acute coronary syndromes who do not meet these criteria can continue to receive the drug until it is appropriate to stop.

View Efient drug record

NICE guidance on prasugrel


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

NICE approves lubiprostone for chronic constipation and revises prasugrel guidance

NICE approves lubiprostone for chronic constipation and revises prasugrel guidance

NICE has approved lubiprostone for the treatment of...

Phase III success for platelet inhibitor

Phase III success for platelet inhibitor

A new antiplatelet drug has outperformed the current...

Clopidogrel and PPIs

The joint manufacturers of Plavix (clopidogrel) have...

Efient

Efient

Lilly has launched Efient (prasugrel) for the prevention...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases